Mode
Text Size
Log in / Sign up

Depression and anxiety prevalence in Behđet's disease reaches approximately 47.44% and 48.48% respectivelyBehçet's disease is linked to high rates of anxiety and depression

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note the high prevalence of depression (47.44%) and anxiety (48.48%) in patients with Behđet's disease.

This meta-analysis synthesized data from 17 studies to determine the prevalence of mental health comorbidities in patients with Behđet's disease. The analysis included 16 studies for depression and 11 studies for anxiety. The pooled prevalence for depression was 47.44% (95% CI: 34.09-60.97%), while the pooled prevalence for anxiety was 48.48% (95% CI: 35.40-61.67%).

Significant geographic variations were noted in the data. For example, depression prevalence was reported as high as 88.83% in Egypt and as low as 5.00% in France. Anxiety prevalence was reported as 92.00% in Egypt and 29.31% in Brazil. These variations suggest that regional factors or specific assessment tools may influence reported rates.

The authors noted substantial heterogeneity (I2 > 90%) as a primary limitation of the study. Despite this, the findings suggest a high prevalence of mental health issues in patients with Behđet's disease. Clinicians should consider the integration of routine mental health screening into the standard management of Behđet's disease to address these common comorbidities.

How this fits prior evidence

This meta-analysis addresses a gap in understanding the prevalence of mental health comorbidities specifically in Behđet's disease. While previous evidence noted that anti-inflammatory strategies may stabilize mental functioning and promote autonomic and metabolic balance, this study provides specific prevalence data for depression and anxiety in this specific inflammatory condition. It also highlights the significant impact of geography and tools on reported rates, similar to how tool-dependent variation was noted in childhood-onset lupus.

Living with Behçet's disease involves more than just physical symptoms. New data shows that many patients also struggle with significant mental health challenges. A review of 17 different studies found that nearly half of the people with this condition also deal with depression or anxiety.

The numbers vary greatly depending on where a person lives. For example, rates of depression and anxiety were much higher in Egypt, while they were lower in France and Brazil. These differences suggest that local factors or different ways of measuring symptoms might change how common these issues appear in different regions.

Because these mental health issues are so common, experts suggest that doctors should include mental health checks as a standard part of caring for patients with Behçet's disease. While the data shows a clear link, the wide range of results across different studies means we are still learning about the exact factors that cause these differences.

What this means for you:
Nearly half of people with Behçet's disease also experience anxiety or depression.

Common questions

How common is depression in people with Behçet's disease?

The study found a pooled prevalence of 47.44% for depression among patients with Behçet's disease. This means nearly half of the patients studied reported symptoms of depression. However, rates varied by location, reaching as high as 88.83% in Egypt and as low as 5.00% in France.

How common is anxiety in people with Behçet's disease?

The study found a pooled prevalence of 48.48% for anxiety in patients with Behçet's disease. Similar to depression, the rates varied by region, with 92.00% reported in Egypt and 29.31% reported in Brazil.

Why do the numbers for anxiety and depression vary so much?

The study noted significant variation based on the assessment tools used and the geographic regions where the data was collected. Because of these differences, it can be hard to determine a single universal rate for every patient.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
BACKGROUND: Behçet's disease (BD) is a chronic multisystemic vasculitis associated with significant physical and psychological morbidity, including depression and anxiety. This systematic review and meta-analysis aimed to estimate the pooled prevalence of depression and anxiety among BD patients and to examine variations by assessment tools and geographic regions. METHOD: Following PRISMA guidelines, a comprehensive search of PubMed, EMBASE, and Scopus was conducted up to April 2025. Data were extracted and quality-assessed using standardized tools, and pooled prevalence rates were calculated via random-effects meta-analysis. RESULTS: A total of 17 studies were included in the systematic review, of which 16 contributed to the meta-analysis of depression and 11 to the meta-analysis of anxiety among patients with BD. The results revealed a high pooled prevalence of depression at 47.44% (95% CI: 34.09-60.97%) and anxiety at 48.48% (95% CI: 35.40-61.67%), both with substantial heterogeneity (I² > 90%). Depression prevalence varied significantly by diagnostic instrument, with PHQ-9 and HADS reporting higher rates compared to DSM-IV and MINI. Geographic differences were marked, with Egypt showing the highest prevalence for both depression (88.83%) and anxiety (92.00%), while France reported the lowest prevalence for depression (5.00%) and Brazil reported the lowest for anxiety (29.31%). No publication bias was detected. CONCLUSION: The findings underscore a high burden of mental health comorbidities in BD, with pooled prevalence rates of 47.44% for depression and 48.48% for anxiety, reflecting significant psychological morbidity. Geographic disparities, suggest cultural, healthcare, or socioeconomic moderators requiring further investigation. These results advocate for integrating routine mental health screening into BD management to address unmet psychiatric needs in this population.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.